Filtered By:
Condition: Pregnancy
Infectious Disease: COVID-19
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 58 results found since Jan 2013.
Letter to the Editor Regarding ‘A neonatal case of cerebral venous sinus thrombosis with intrauterine onset after COVID19 infection during pregnancy: cause or coincidence?’
We read with interest the article by Ozdil et al. about a three day-old female neonate who was diagnosed with venous sinus thrombosis (VST) which was complicated by a subacute, partial ischemic stroke in the territory of the right middle cerebral artery.1 The age of the stroke was estimated at 14-28 days before birth.1 Because the mother suffered a mild coronvirus disease-19 (COVID-19) infection during the initial weeks of the third trimester (gestational weeks 27-30), VST in the fetus was causally related to the severe, acute respiratory syndrome-coronavirus type-2 (SARS-CoV-2) infection of the mother.
Source: Journal of Stroke and Cerebrovascular Diseases - April 7, 2023 Category: Neurology Authors: Josef Finsterer Tags: Letter to the Editor Source Type: research
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Evidence That Increasing Serum 25(OH)D Concentrations to 30 ng/mL in the Kingdom of Saudi Arabia and the United Arab Emirates Could Greatly Improve Health Outcomes
Biomedicines. 2023 Mar 23;11(4):994. doi: 10.3390/biomedicines11040994.ABSTRACTAccumulating evidence supports the potential protective effects of vitamin D against chronic diseases such as Alzheimer's disease, autoimmune diseases, cancers, cardiovascular disease (ischaemic heart disease and stroke), type 2 diabetes, hypertension, chronic kidney disease, stroke, and infectious diseases such as acute respiratory tract diseases, COVID-19, influenza, and pneumonia, as well as adverse pregnancy outcomes. The respective evidence is based on ecological and observational studies, randomized controlled trials, mechanistic studies, ...
Source: Cancer Control - May 16, 2023 Category: Cancer & Oncology Authors: William B Grant Fatme Al Anouti Barbara J Boucher Hana M A Fakhoury Meis Moukayed Stefan Pilz Nasser M Al-Daghri Source Type: research
Protein S: function, regulation, and clinical perspectives
Purpose of review
Protein S (PS) is an essential natural anticoagulant. PS deficiency is a major contributor to acquired hypercoagulability. Acquired hypercoagulability causes myocardial infarction, stroke, and deep vein thrombosis in millions of individuals. Yet, despite its importance in hemostasis, PS is the least understood anticoagulant. Even after 40 years since PS was first described, we are still uncovering information about how PS functions. The purpose of this review is to highlight recent findings that advance our understanding of the functions of PS and explain hypercoagulability caused by severe PS defic...
Source: Current Opinion in Hematology - August 6, 2021 Category: Hematology Tags: HEMOSTASIS AND THROMBOSIS: Edited by Paul F. Bray Source Type: research
Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases
Vasa. 2022 Oct 6. doi: 10.1024/0301-1526/a001031. Online ahead of print.ABSTRACT Vascular adhesion protein-1 (VAP-1) also known as amino oxidase copper containing 3 (AOC3) is a pro-inflammatory and versatile molecule with adhesive and enzymatic properties. VAP-1 is a primary amine oxidase belonging to the semicarbazide-sensitive amine oxidase (SSAO) family, which catalyzes the oxidation of primary amines leading to the production of ammonium, formaldehyde, methylglyoxal, and hydrogen peroxide. VAP-1 is mainly expressed by endothelial cells, smooth muscle cells, adipocytes and pericytes. It is involved in a repertoire of bi...
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - October 6, 2022 Category: Surgery Authors: Marianna Danielli Roisin Clare Thomas Lauren Marie Quinn Bee Kang Tan Source Type: research
